Nerandomilast is an oral, selective phosphodiesterase 4B (PDE4B) inhibitor, now approved in China for the treatment of both idiopathic pulmonary fibrosis (IPF) and PPF in adults. In the United States, the drug has been granted Priority Review and Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and is already approved for the treatment of IPF. Currently, the FDA is conducting a Priority Review of nerandomilast for the treatment of adult PPF.

Since the third quarter of this year, Fosun Pharma has executed multiple license deals. The company has successively entered into transactions with Sitala and Expedition for FXS6837, intended for the treatment of diseases related to immunomodulation, and XH-S004, intended for the treatment of non-cystic fibrosis bronchiectasis, respectively.

The commercial success of radiopharmaceuticals has attracted more innovative pharmaceutical companies to this field. Beyond Novartis, multinational corporations (MNCs) such as Eli Lilly, Bristol Myers Squibb (BMS), AstraZeneca, and Roche are actively developing therapeutic radiopharmaceuticals.

Remibrutinib is a Bruton's tyrosine kinase inhibitor (BTKi) developed by Novartis. It works by targeting and blocking the BTK signaling pathway, thereby inhibiting the release of histamine and other pro-inflammatory mediators from mast cells.

Durvalumab is a humanized monoclonal antibody targeting PD-L1. It works by blocking the interaction between PD-L1 and its receptors PD-1 and CD80, thereby countering tumor immune evasion and reactivating suppressed immune responses.

Information indicates that Dren Bio's targeted myeloid cell engager and phagocytosis platform is a bispecific antibody-based technology. It facilitates the effective depletion of pathogenic cells, protein aggregates, and other disease-causing factors by engaging a novel phagocytic receptor selectively expressed on myeloid cells.

Since the beginning of this year, in addition to the renewed agreement with AstraZeneca, Harbour BioMed has entered into multiple licensing deals and collaborations with various companies globally.

The approval covers pediatric patients aged 12 years and older and adult patients weighing ≥35 kg who have severe Hemophilia A (congenital Factor VIII deficiency, FVIII <1%) without Factor VIII inhibitors, or severe Hemophilia B (congenital Factor IX deficiency, FIX <1%) without Factor IX inhibitors.

In terms of market performance, significant corrections have recently been observed in the innovative drug sector across both the Hong Kong and A-share markets. Based on our analysis of the constituent stocks of the Hong Kong Innovative Drug Index and A-share innovative pharmaceutical companies, most of these companies have seen declining stock prices since August 1st, with the steepest drop approaching 50%.

This marketing application is not the first time seladelpar has entered the Chinese public view. In August 2025, the drug was approved under Beijing's clinical urgent import policy within the Beijing Tianzhu Rare Disease Drug Security Pilot Zone. It was designated for use in combination with ursodeoxycholic acid (UDCA) for adult PBC patients who have responded inadequately to UDCA, or as a monotherapy for those intolerant to UDCA. The current acceptance of the application by the CDE indicates that seladelpar is now positioned to potentially benefit Chinese patients through the formal regulatory approval pathway.

Tirzepatide, a dual GLP-1R/GIPR agonist, is approved in China for three indications: glycemic control in adults with type 2 diabetes, long-term weight management, and obstructive sleep apnea. A fourth application submitted in December 2024 is speculated by the Insight database to be for heart failure with preserved ejection fraction (HFpEF) with obesity.

Driven by an explosive growth in innovative drug and high-end medical device transactions in recent years, this year's CIIE has effectively become a "super showcase" for numerous international pharmaceutical and device companies to jointly present innovative products developed in collaboration with local partners.

VCBeat is set to launch Global Pharma Focus, a dedicated segment that examines the strategic dynamics of multinational pharmaceutical companies through a global lens.

Novo Nordisk is executing a "strategic slimming." This is not a retreat, but a disciplined trade-off: shedding exploratory possibilities in exchange for the leanness and agility needed to secure absolute leadership in its core business.

On November 8, Eli Lilly entered into a collaboration agreement with SanegeneBio, valued at up to $1.2 billion, to jointly develop and commercialize RNAi therapies for metabolic diseases. Shortly before this, on October 30, Innovent Biologics disclosed its siRNA patent WO2025223537A1, covering progress in the development of small nucleic acid drugs targeting INHBE.

Under the agreement, Insilico will apply its extensively validated Pharma.AI platform and professional drug discovery capabilities to generate, design, and optimize candidate compounds for innovative targets identified by both parties.

As one of the most popular sections in previous CIIEs, the Medical Equipment and Healthcare Products exhibition area moved to Halls 1.1, 1.2, and 2.2 this year. The world’s top ten medical device giants and 12 Fortune Global 500 pharmaceutical companies gathered in this expansive space exceeding 70,000 square meters.

SanegeneBio will be responsible for screening and identifying optimal RNAi active molecules for the collaborative projects using its LEAD™ platform, while Eli Lilly will oversee subsequent IND-enabling studies, clinical development, and commercialization.

The approval covers its use in combination with plasma exchange and immunosuppressive therapy for the treatment of adult and adolescent patients (aged 12 years and older, weighing at least 40 kg) with acquired thrombotic thrombocytopenic purpura (aTTP, also known as immune-mediated thrombotic thrombocytopenic purpura, iTTP).

Under the theme "Innovation with Purpose, Caring for All," the company showcased nearly 50 innovative products and solutions spanning precision diagnosis and therapy, smart intervention and imaging, and personal health. The display included ten "China debut" products and over ten AI-enabled health technology solutions.